Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Cellular Therapies - T Cells - Brexucabtagene autoleucel, cryopreserved - T - Tecartus - Injection, intravenous infusion - Bag, Gilead Sciences Pty Ltd, CON-1037
Product name
Cellular Therapies - T Cells - Brexucabtagene autoleucel, cryopreserved - T - Tecartus - Injection, intravenous infusion - Bag
Sponsor name
Gilead Sciences Pty Ltd
Consent start
Consent no.
CON-1037
Standard
TGO 107: Schedule 2, Part 1, Item 6 of Therapeutic Goods (Standard for Biologicals - Labelling Requirements) (TGO 107) Order 2021
Non-compliance with standard
The product does not conform to the requirements of Schedule 2, Part 1, Item 6
of TGO 107 in that the name of the sponsor of the biological is not on the
product label attached to the container.
Therapeutic product type
Blood, tissues, and biologicals